Biological
CTX112
CTX112 is a biological therapy with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
not_yet_recruiting133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
not_yet_recruitingphase_1
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
NCT07549698
recruitingphase_1
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542
recruitingphase_1
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
NCT05643742
Clinical Trials (3)
Showing 3 of 3 trials
NCT07549698Phase 1
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
NCT06925542Phase 1
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT05643742Phase 1
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3